INVO Bioscience Announces Completion of Registrations in Bulgaria and Venezuela

BEVERLY, MA--(Marketwire - April 15, 2010) - INVO Bioscience, Inc. (OTCBB: IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, announced today that the product registrations required for sale have been completed for Bulgaria in Europe and Venezuela, South America

As previously announced in January, the company has signed a distribution agreement with BioGenini Medical EOOD. BioGenini along with INVO has worked with the Bulgarian government and completed the registration process for the INVOcell. BioGenini Medical is the first distribution partner for INVO Bioscience in Europe and they can now begin calling on doctors for the sale of the INVOcell in Bulgaria. INVO and BioGenini plan on launching the INVOcell during a Bulgarian national infertility conference held in June. Additionally, BioGenini has agreed to import and ship to the individual customers in other European countries who have requested the purchase of the INVO cell. This is a step that allows us to get the INVOcell to some of the physicians in Europe who have made direct requests to INVO Bioscience but could not receive product due to lack of European distributorship.

The registration in Venezuela will allow Daxley, INVO Biosciences’ distributor, to begin selling in this country. Some doctors have already been trained in Venezuela and Dr. Sonoja in Venezuela was the first physician to perform the INVO procedure that resulted in the first baby being born in this country.

Registrations are in process for several other Latin American countries including Brazil and Argentina.

INVO Bioscience’s patented product, the INVOcell, allows for vaginal incubation of eggs, sperm and early embryo development during the infertility treatment process. “These registrations will enable INVO Bioscience to continue towards our goal of treating patients with the INVO procedure in countries around the world where couples cannot afford or access treatment,” said INVO Bioscience CEO Kathleen Karloff.

About INVO Bioscience
INVO Bioscience (IVOB) is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company’s lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman’s vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit www.invobioscience.com.

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.